CL2021000858A1 - Derivados de 4-pirazin-2-ilmetil-morfolina y su uso como medicamento - Google Patents

Derivados de 4-pirazin-2-ilmetil-morfolina y su uso como medicamento

Info

Publication number
CL2021000858A1
CL2021000858A1 CL2021000858A CL2021000858A CL2021000858A1 CL 2021000858 A1 CL2021000858 A1 CL 2021000858A1 CL 2021000858 A CL2021000858 A CL 2021000858A CL 2021000858 A CL2021000858 A CL 2021000858A CL 2021000858 A1 CL2021000858 A1 CL 2021000858A1
Authority
CL
Chile
Prior art keywords
pyrazin
ylmethyl
morpholine
medicine
derivatives
Prior art date
Application number
CL2021000858A
Other languages
English (en)
Inventor
Dieter Wiedenmayer
Riccardo Giovannini
Angelo Ceci
Cornelia Dorner-Ciossek
Roland Pfau
Original Assignee
Boehringer Ingelheim Int
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Boehringer Ingelheim Int filed Critical Boehringer Ingelheim Int
Publication of CL2021000858A1 publication Critical patent/CL2021000858A1/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
    • C07D413/06—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
    • C07D405/10—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a carbon chain containing aromatic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A61K31/5375—1,4-Oxazines, e.g. morpholine
    • A61K31/5377—1,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/02—Drugs for disorders of the nervous system for peripheral neuropathies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/22—Anxiolytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/26—Psychostimulants, e.g. nicotine, cocaine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Biomedical Technology (AREA)
  • Psychiatry (AREA)
  • Pain & Pain Management (AREA)
  • Epidemiology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Rheumatology (AREA)
  • Immunology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Nitrogen And Oxygen As The Only Ring Hetero Atoms (AREA)

Abstract

La presente invención se refiere a 4-pirazin-2-ilmetil-morfolinas novedosas de la Fórmula general A, procesos para su preparación, composiciones farmacéuticas que las contienen y su uso en tratamientos, particularmente, en el tratamiento o la prevención de afecciones que tienen una relación con las propiedades de modulación alostérica negativa de NR2B.
CL2021000858A 2018-10-17 2021-04-07 Derivados de 4-pirazin-2-ilmetil-morfolina y su uso como medicamento CL2021000858A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
EP18200943 2018-10-17

Publications (1)

Publication Number Publication Date
CL2021000858A1 true CL2021000858A1 (es) 2021-10-01

Family

ID=63878518

Family Applications (1)

Application Number Title Priority Date Filing Date
CL2021000858A CL2021000858A1 (es) 2018-10-17 2021-04-07 Derivados de 4-pirazin-2-ilmetil-morfolina y su uso como medicamento

Country Status (38)

Country Link
US (2) US11166958B2 (es)
EP (1) EP3867244B1 (es)
JP (1) JP7093468B2 (es)
KR (1) KR102840105B1 (es)
CN (1) CN112888685B (es)
AR (1) AR116711A1 (es)
AU (1) AU2019362330B2 (es)
BR (1) BR112021004993A2 (es)
CA (1) CA3113308A1 (es)
CL (1) CL2021000858A1 (es)
CO (1) CO2021004612A2 (es)
CR (1) CR20210184A (es)
DK (1) DK3867244T3 (es)
DO (1) DOP2021000069A (es)
EA (1) EA202191014A1 (es)
EC (1) ECSP21027009A (es)
ES (1) ES2940184T3 (es)
FI (1) FI3867244T3 (es)
HR (1) HRP20230249T1 (es)
HU (1) HUE061891T2 (es)
IL (1) IL282142B2 (es)
JO (1) JOP20210075A1 (es)
LT (1) LT3867244T (es)
MA (1) MA53898B1 (es)
MX (1) MX2021004418A (es)
MY (1) MY205127A (es)
NZ (1) NZ773672A (es)
PE (1) PE20211278A1 (es)
PH (1) PH12021550834A1 (es)
PL (1) PL3867244T3 (es)
PT (1) PT3867244T (es)
RS (1) RS63988B1 (es)
SA (1) SA521421756B1 (es)
SG (1) SG11202103806VA (es)
SI (1) SI3867244T1 (es)
TW (1) TWI828779B (es)
UA (1) UA128408C2 (es)
WO (1) WO2020079039A1 (es)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US11376258B2 (en) * 2019-06-04 2022-07-05 Boehringer Ingelheim International Gmbh Purine derivatives and the use thereof as medicament

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6495561B2 (en) 1999-10-29 2002-12-17 Merck & Co., Inc. 2-cyclohexyl imidazopyridine NMDA/NR2B antagonists
JP2005511478A (ja) 2001-04-03 2005-04-28 メルク　エンド　カムパニー　インコーポレーテッド Ｎ−置換非アリール複素環アミジル系ｎｍｄａ／ｎｒ２ｂ拮抗薬
SI1409477T1 (sl) * 2001-07-24 2009-02-28 Richter Gedeon Nyrt Derivati piperidina kot antagonisti nmda-receptorjev
CA2630517A1 (en) * 2005-12-06 2007-06-14 Merck & Co., Inc. Morpholine carboxamide prokineticin receptor antagonists
WO2010088414A2 (en) * 2009-01-28 2010-08-05 Emory University Subunit selective nmda receptor potentiators for the treatment of neurological conditions
WO2012128582A2 (en) 2011-03-23 2012-09-27 Hyundai Pharm Co., Ltd. A COMPOUND FOR INHIBITING HUMAN 11-β-HYDROXY STEROID DEHYDROGENASE TYPE 1, AND A PHARMACEUTICAL COMPOSITION COMPRISING THE SAME
ES2599553T3 (es) 2012-10-18 2017-02-02 F. Hoffmann-La Roche Ag Derivados de etinilo como moduladores de la actividad del receptor mGluR5
CN106255679B (zh) * 2014-02-27 2019-09-06 默克专利有限公司 用作nav通道抑制剂的杂环化合物及其用途
US10913736B2 (en) 2014-08-22 2021-02-09 University Of Washington Specific inhibitors of methionyl-tRNA synthetase
JP6843853B2 (ja) * 2015-10-14 2021-03-17 ブリストル−マイヤーズ スクイブ カンパニーＢｒｉｓｔｏｌ−Ｍｙｅｒｓ Ｓｑｕｉｂｂ Ｃｏｍｐａｎｙ 選択的ｎｒ２ｂアンタゴニスト

Also Published As

Publication number Publication date
LT3867244T (lt) 2023-03-10
CO2021004612A2 (es) 2021-04-30
IL282142A (en) 2021-05-31
HUE061891T2 (hu) 2023-09-28
DOP2021000069A (es) 2021-05-31
EP3867244B1 (en) 2023-01-18
AU2019362330B2 (en) 2024-03-28
ES2940184T3 (es) 2023-05-04
SI3867244T1 (sl) 2023-04-28
SG11202103806VA (en) 2021-05-28
MA53898B1 (fr) 2023-03-31
US20210393644A1 (en) 2021-12-23
NZ773672A (en) 2024-12-20
RS63988B1 (sr) 2023-03-31
PL3867244T3 (pl) 2023-05-22
EA202191014A1 (ru) 2021-11-09
TWI828779B (zh) 2024-01-11
US11166958B2 (en) 2021-11-09
BR112021004993A2 (pt) 2021-06-08
ECSP21027009A (es) 2021-05-31
MY205127A (en) 2024-10-03
PE20211278A1 (es) 2021-07-19
UA128408C2 (uk) 2024-07-03
JOP20210075A1 (ar) 2023-01-30
DK3867244T3 (da) 2023-05-01
US20200121691A1 (en) 2020-04-23
PT3867244T (pt) 2023-02-22
MA53898A (fr) 2022-01-26
CN112888685A (zh) 2021-06-01
EP3867244A1 (en) 2021-08-25
HRP20230249T1 (hr) 2023-04-14
MX2021004418A (es) 2021-07-06
AR116711A1 (es) 2021-06-02
KR102840105B1 (ko) 2025-07-31
PH12021550834A1 (en) 2021-10-04
CN112888685B (zh) 2023-09-22
WO2020079039A1 (en) 2020-04-23
CR20210184A (es) 2021-05-26
KR20210079325A (ko) 2021-06-29
JP7093468B2 (ja) 2022-06-29
AU2019362330A1 (en) 2021-04-08
IL282142B1 (en) 2023-12-01
TW202031262A (zh) 2020-09-01
IL282142B2 (en) 2024-04-01
SA521421756B1 (ar) 2023-02-12
CA3113308A1 (en) 2020-04-23
JP2022505080A (ja) 2022-01-14
FI3867244T3 (fi) 2023-03-20

Similar Documents

Publication Publication Date Title
ECSP20040257A (es) Nuevas piridopirimidinonas sustituidas con bencilamino y derivados como inhibidores de sos1
SV2018005778A (es) Derivados aromaticos de sulfonamida
SV2017005461A (es) Benzamidas sustituidas con 1,3-tiazol-2-ilo
CO2018004857A2 (es) Derivados de dihidroimidazopirazinona usados en el tratamiento del cáncer
CR20160006A (es) Derivados de pirrolamida sustituidos con glioxamida y su uso como medicamentos para el tratamiento de la hepatitis b
MX2019012847A (es) Compuestos de c5-anilinoquinazolina y su uso en el tratamiento del cancer.
ECSP18073293A (es) Derivados de indolina sustituidos como inhibidores de la replicación viral del dengue
CU20190101A7 (es) Imidazopirimidinas diazabicíclicas sustituidas
CR20160433A (es) Nuevos compuestos
CL2021001388A1 (es) Compuestos útiles en la terapia para el vih
CL2021000329A1 (es) Compuestos útiles en terapia del vih
MX2016015437A (es) Combinacion que comprende un glucocorticoide y edo-s101.
CO2019009020A2 (es) Derivados de pirazol como inhibidores de bromodominio.
MX2018008640A (es) Derivados de 3-(carboxietil)-8-amino-2-oxo-1,3-diaza-espiro-[4.5]- decano.
UY37729A (es) NUEVOS COMPUESTOS QUE INHIBEN LA ACTIVIDAD DE Nav1.7
CL2020001402A1 (es) Derivados de imidazopiridina y su uso como medicamento.
CL2017000884A1 (es) Composición farmacéutica para usarse en el tratamiento o la prevención de deficiencias de vitaminas y minerales en pacientes que han sido sometidos a cirugía de derivación gástrica
BR112018008076A2 (pt) derivados de lapachona contendo dois centros redox e métodos de uso dos mesmos
MX2017006476A (es) Terapia de combinacion efectiva contra microorganismos, que incluye microorganismos resistentes a farmacos.
CL2021000858A1 (es) Derivados de 4-pirazin-2-ilmetil-morfolina y su uso como medicamento
BR112017009850A2 (pt) composto, composição, e, uso de uma quantidade melhoradora de hiv de um composto
CL2017002229A1 (es) Inhibidores de bace1.
BR112019017314A2 (pt) composições farmacêuticas para terapia de combinação
UY36273A (es) Composicion para el tratamiento de neuropatías y del dolor neuropático
BR112017014295A2 (pt) composição farmacêutica.